111, Inc. Sponsored ADR (NASDAQ:YI – Get Free Report) saw a significant decrease in short interest during the month of October. As of October 15th, there was short interest totaling 4,313 shares, a decrease of 38.5% from the September 30th total of 7,014 shares. Based on an average daily trading volume, of 12,201 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.1% of the company’s shares are sold short.
111 Stock Up 6.2%
Shares of NASDAQ YI opened at $3.03 on Tuesday. The firm has a market cap of $26.60 million, a price-to-earnings ratio of -1.89 and a beta of 0.67. 111 has a 52-week low of $2.48 and a 52-week high of $11.17. The business’s 50 day moving average is $3.32 and its two-hundred day moving average is $5.04.
111 (NASDAQ:YI – Get Free Report) last released its quarterly earnings results on Friday, September 18th. The company reported ($0.60) EPS for the quarter. The business had revenue of $338.55 million during the quarter.
Analyst Ratings Changes
Separately, Weiss Ratings cut shares of 111 from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, October 13th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, 111 has a consensus rating of “Sell”.
About 111
111, Inc is a China-based healthcare technology company that operates an online platform connecting consumers, pharmaceutical manufacturers, distributors and healthcare providers. The company focuses on improving access to medicines and health-related products through digital retail and supply-chain services.
Its business includes online sales of prescription and over-the-counter medicines, nutritional products, medical devices and other healthcare products. Through its technology platform, 111 also provides services intended to support pharmaceutical companies and pharmacies with product distribution, marketing, data and fulfillment.
Founded in 2010 and headquartered in Shanghai, 111 serves customers and healthcare businesses in China.
See Also
- Five stocks we like better than 111
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for 111 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 111 and related companies with MarketBeat.com's FREE daily email newsletter.
